Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

Hyderabad, <keyword id="138856" type="DOMAIN" weightage="20" keywordseo="Aurobindo-Pharma-Ltd">Aurobindo Pharma Ltd</keyword> and Covaxx, a US-based company, have entered into an <keyword id="10489747" type="UNKNOWN" weightage="20" keywordseo="exclusive-license-agreement">exclusive license agreement</keyword> to develop, commercialise and manufacture UB-612, the first Multitope Peptide-based vaccine to fight COVID-19, for <keyword id="3658" type="LOCATION" weightage="20" keywordseo="India">India</keyword> and UNICEF. According to a release issued by the city-based drug maker, Covaxx is currently conducting a Phase 1 clinical trial for the vaccine candidate. Managing Director of <keyword id="70473" type="DOMAIN" weightage="20" keywordseo="Aurobindo-Pharma">Aurobindo Pharma</keyword> Ltd, N Govindarajan, said, "We are proud to partner with Covaxx in developing the first-ever synthetic peptide-based vaccine to combat the <keyword id="8902449" type="UNKNOWN" weightage="20" keywordseo="covid-19-pandemic">COVID-19 pandemic</keyword>. This vaccine has immense potential in eliminating shedding, and hence containing, the spread of the pandemic." Under the signed agreement, Aurobindo Pharma has obtained the exclusive rights to develop, manufacture and sell Covaxxs UB-612 vaccine in India and to UNICEF, as well as non-exclusive rights in other select emerging and developing markets, it said. Aurobindo Pharma and Covaxx are partnering on clinical development, manufacturing and marketing of the vaccine candidate. Aurobindo will manufacture the finished doses at its facilities in Hyderabad. It has the capacity of manufacturing 220 million doses in multi-dose presentation and is building additional facilities to have a total capacity of nearly 480 million doses by June 2021. Mei Mei Hu, co-founder and CEO of Covaxx said his company is committed to providing an equitable distribution of UB-612 by prioritizing emerging markets where there is the unmet need. "During this global health crisis response, we must establish partners with the strongest capabilities, like Aurobindo, to prioritize the development and the delivery of our vaccine. As one of the leading industry players with a strong track record of execution and investment in vaccines, Aurobindo Pharma is the ideal partner to advance UB-612 in India and other emerging nations and to support our mission of democratizing health worldwide," Hu said. SEE ALSO: <a href="https://www.businessinsider.in/stock-market/news/top-stocks-to-watch-mrs-bectors-ril-bharti-airtel-vodafone-idea-ilfs-interglobe-aviation-future-group-deepak-nitrite-jubilant-foodworks-and-others/articleshow/79933826.cms">Top stocks to watch – Mrs Bectors, RIL, Bharti Airtel, Vodafone Idea, IL&amp;FS, InterGlobe Aviation, Future Group, Deepak Nitrite, Jubilant FoodWorks, and others</a> <a href="https://www.businessinsider.in/thelife/personalities/news/from-taking-on-yahoo-to-being-tamed-by-chinas-communist-party-its-been-a-roller-coaster-decade-for-jack-ma/slidelist/79935613.cms">From taking on Yahoo to being tamed by China’s Communist Party— it’s been a roller coaster decade for Jack Ma</a> <a href="https://www.businessinsider.in/careers/news/ey-is-looking-to-hire-9000-techies-in-2021-to-boost-its-digital-services/articleshow/79936576.cms">EY is looking to hire 9,000 techies in 2021 to boost its digital services</a>

Aurobindo Pharma join hands with US-based company Covaxx to develop COVID-19 vaccine for India

You Searched For "first multitope peptide" and got 1 results

Aurobindo Pharma join hands with US-based company Covaxx to develop COVID-19 vaccine for India

PTI

Popular Keywords

Buying Guides